Valeant posts FY23 revenue of $7.8 bln, up 42% YoY.

Tuesday, Jan 13, 2026 11:51 am ET1min read
BHC--
BLCO--

• Valeant Pharmaceuticals International reports unaudited pro forma condensed combined financial information • Gives effect to Bausch & Lomb acquisition by Valeant and Medicis acquisition by Valeant • Includes debt and equity issuance to finance Bausch & Lomb acquisition • Medicis acquisition took place on December 11, 2012 • Valeant issued term loan and senior notes to finance Medicis acquisition • Unaudited pro forma condensed combined statements of loss for fiscal year ended December 31, 2012, and three months ended March 31, 2013.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet